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Acromegaly 
Ariel L. Barkan 
In the majority of cases, acromegaly is due to GH hypersecretion by a 
somatotroph pituitary tumor. The etiology of acromegaly is not known, 
and may be related to GHRH hypersecretion, intn’nsic pituitary defect, 
or a combination thereof: Recent physiologic data and molecular 
biology techniques provide insights into the pathophysiology of this 
condition. Treatment options include surgery, radiation, and judicious 
administration of pharmacologic compounds inhibiting GH secretion 
and tumor growth. (Trends Endocrinol Metab 1992;3:205-2 10) 
?? Case Report 
A 5 1 -year-old woman was referred be- 
cause of suspected acromegaly. She was 
known to have hypertension with left 
ventricular hypertrophy for more than 
10 years and had been treated with 
diuretics and p blockers. She also had 
repeated bouts of supraventricular arrhyth- 
mia that were resistant to medical ther- 
apy, and 4 years ago she underwent 
radiofrequency ablation of the atrioven- 
tricular node. She had uterine fibromata 
and 6 years ago underwent abdominal 
hysterectomy. At the time of surgery, the 
anesthesiologist noted that her large 
tongue and excessive palatal soft tissue 
caused difficulty with intubation. Five 
years ago, she began to complain about 
diffuse joint pain and was evaluated by 
several rheumatologists. The diagnoses 
of degenerative joint disease, mixed con- 
nective tissue disease, nonspecific my- 
opathy, and arthropathy of unknown 
origin had been proposed, and some 
relief was obtained with nonsteroidal 
antiinflammatory drugs. She had a long 
history of euthyroid goiter, but she re- 
ceived no thyroxine suppression. She 
also suffered from severe headaches that 
resisted pain medications. A diagnosis of 
depression was entertained and the pa- 
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tient had received counseling over the 
past year. A new rheumatologist noticed 
rough facial features and referred the 
patient to us. Questioning revealed an 
increase in shoe and ring size since age 
30-35, malodorous perspiration, heavy 
snoring, and sleep apnea. The patient 
had obvious acromegaly, with rough 
facial features, multiple skin tags, and 
fleshy and moist hands and feet. There 
was no visual field defect or sign of 
extraocular muscle impairment. She had 
bilateral carpal tunnel syndrome. Mag- 
netic resonance imaging (MRI) revealed 
a 12 x 16 x 20-mm pituitary tumor al- 
most reaching the optic chiasm and 
displacing both cavernous sinuses. Her 
plasma GH ranged between 30 and 70 
pg/L (r&5) and plasma IGF-I was 1400 
pg/L (nlc270). After oral glucose load, 
plasma GH did not decline below 30 clgn 
and, after an intravenous bolus of TRH, 
plasma GH rose from 47 to 672 J.@L. Her 
baseline GH profile (QlO-min sampling 
for 24 h) is shown in Figure 1. 
Acromegaly is a chronic debilitating 
disease characterized by persistent GH 
and IGF-I hypersecretion. Clinical pres- 
entation of patients with acromegaly is 
unmistakable: coarse facial features with 
pronounced skin folds, large hands and 
feet with obvious excess of soft tissue, 
and excessive perspiration are seen vir- 
tually in every patient. Careful history 
reveals presence of these signs for 5-15 
years prior to diagnosis, during which 
time a multitude of other diagnoses are 
often entertained and various treatments 
applied. Acromegaly is probably the best 
example of the maxim that one finds 
only what one is looking for. The patient 
presented here had multiple symptoms 
and signs related to acromegaly, includ- 
ing arthropathy, heart disease, goiter, 
headache, and soft tissue hypertrophy 
for many years before an astute physi- 
cian made the correct diagnosis. Once 
suspected, however, acromegaly is easily 
confirmed by appropriate laboratory tests. 
Pathophysiology 
The patient had mild hyperprolactin- The most obvious clinical manifestation 
emia (27 cLg/L; nlc20) but normal thyroid of acromegaly, that is, excessive growth, 
and adrenal function, and plasma LH is limited to acral enlargement if the 
and FSH were elevated appropriately for disease process starts after closure of the 
her age. She was begun on injections of epiphyses, or may include accelerated 
the long-acting somatostatin analogue statural growth (gigantism) if the disease 
octreotide, 100 pg t.i.d. subcutaneously. process begins well before puberty. In 
Her headaches vanished almost immedi- light of this clear clinical distinction, it is 
ately and arthritic pain improved within of interest that even though the disease is 
1 month. There was also a significant usually diagnosed during the third or 
decrease in soft tissue hypertrophy and fourth decade of life, the average height 
abolition of excess perspiration, snoring, of the patients is 5-6 cm above the ethnic 
and sleep apnea. After 4 months of 
therapy, her plasma GH was < 1.5 pg/L in 
multiple samples, and plasma IGF-I fell 
to 4 10 &L. Repeat MRI disclosed shrink- 
age (Figure 2) of her pituitary tumor 
(8 x 12 x 16 mm). At transsphenoidal 
surgery, the tumor was very soft and was 
easily removed. The postoperative 
course was uneventful. One year after 
surgery, she is in a good general health, 
with normal plasma IGF-I levels, ran- 
dom GH levels c 1.5 pg/L., and disappear- 
ance of the GH response to TRH. Adrenal 
and thyroid function remain normal. 
She still has vague joint pain, but there 
was a complete resolution of headache, 
carpal tunnel syndrome, and depression. 
She remains hypertensive and continues 
on diuretics and /3 blockers. 
?? Discussion 
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Figure 1. Pulsatile GH profiles in a patient with acromegaly (left) and in age-, sex-, and body 
mass index-matched control (right). Plasma GH was measured every 10 min for 24 h, and the data 
were subjected to cluster analysis. GH pulses are marked above each profile. 
mean, and their siblings and parents are the expected pubertal growth spurt. It is, 
also unusually tall (Perheentupa et al. therefore, tempting to speculate that 
1986). This height excess appears to be there may be some genetic tendency for 
arrived at during or immed.iately after increased GH secretion that may culmi- 
Figure 2. Pituitary MRI scans before (left) and after (right) 4 months of therapy with 
octreotide acetate, 100 Fg every 8 h subcutaneously. 
nate as a clinical disease in some individ- 
uals and that acromegaly is a disease of 
peripubertal onset. Indeed, during pu- 
berty there is a significant augmentation 
of GH secretion (Mauras et al. 1987) and 
the plasma levels of IGF-I increase dra- 
matically, often reaching levels that are 
seen in active acromegaly. The acceler- 
ated somatic growth, disproportionate 
growth of hands and feet, roughening of 
facial features, and increased perspira- 
tion and oiliness of skin that occur 
during normal puberty all resemble 
acromegaly. Of course, this stage is 
transient and a gradual decrease in GH 
secretion toward the functional GH defi- 
ciency of old age begins shortly after 
puberty. However, unusually tall chil- 
dren exhibit biochemical abnormalities 
of GH secretion usually associated with 
acromegaly, such as incomplete GH 
suppression by glucose, GH responses to 
TRH, and augmented GH responses to 
GHRH, and most have radiologic evi- 
dence of enlarged pituitary gland often 
resembling an adenoma (Batrinos et al. 
1987; Hindmarsh et al. 1986). The physi- 
ologic processes underlying augmenta- 
tion of GH secretion at puberty and its 
subsequent decline during adulthood are 
unknown. Similarly, it is not known 
whether failure of the postpubertal re- 
straint mechanism may result in persis- 
tently high GH secretion with subse- 
quent development of acromegaly. 
The question of whether acromegaly is 
a pituitary or a hypothalamic disease has 
been debated for decades. Until recently, 
however, there were no tools to answer 
this question. Previous studies have con- 
centrated on the description of GH re- 
sponses to various suppressive and stimu- 
latory pharmacologic compounds purport- 
edly acting on the pituitary or the hypo- 
thalamus. Recent insights into physiology 
and cell biology of different components 
of the GH-secreting system promise to 
provide a more direct understanding of 
the physiopathology of acromegaly. 
GH is produced and secreted exclu- 
sively by the pituitary somatotrophs. Hy- 
pothalamic regulation of GH secretion is 
accomplished by an interplay of two 
factors: GHRH and somatostatin (SRIF). 
Animal studies have demonstrated con- 
vincingly that both neurohormones are 
secreted periodically and, likely, 180” out 
of phase. Periodic pulses of GHRH are 
primarily responsible for the generation 
of GH pulses while tonic SRIF secretion 
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maintains low interpulse GH levels (Plotsky 
and Vale 1985; Frohman et al. 1990). 
Additionally, periodic declines in SRIF 
secretion may promote acute discharges 
of GHRH and augment pituitary responses 
to GHRH pulses. Our understanding of 
the neuroendocrine mechanisms govem- 
ing GH pulsatility in humans is likely to 
become more comprehensive in the near 
future as a result of the recent develop- 
ment of ultrasensitive (- 5 pg/mL) chemi- 
luminescent GH assays. GHRH is a potent 
mitogenic agent for pituitary somatotrophs 
and it also induces GH gene transcription 
and GH release (Billestrup et al. 1986). A 
simplified scheme of neuroendocrine and 
cellular events leading to somatotroph 
proliferation and GH synthesis and secre- 
tion is shown in Figure 3. Since 
acromegaly is associated with both GH 
hypersecretion and increased somatotroph 
proliferation, it is likely that the underly- 
ing mechanism(s) of this disease involve 
an abnormality somewhere along this 
pathway. Thus, both GHRH excess (hy- 
pothalamic cause) as well as an ab- 
normality in the intracellular components 
of the pathway (pituitary cause) may be 
responsible for the initiation and progres- 
sion of the disease. Additionally, a combi- 
nation of both the GHRH excess and 
pituitary mutation (a “two stage” hypothe- 
sis) should be considered (Melmed 1990). 
According to this theory, primary pitu- 
itary mutation is an initiating event, and 
GHRH excess leads to clonal expansion of 
the mutant somatotroph. Conversely, ac- 
celerated somatotroph proliferation as a 
result of GHRH-induced mitogenesis may 
render somatotrophs prone to developing 
mutations (Butterworth and Goldsworthy 
1991), likely along the GHRH-activated 
pathway. Several recent experimental para- 
digms and some clinical correlates pro- 
vide support to each of these possibilities. 
Accelerated GH pulse frequency (3-4 
times normal) in patients with 
acromegaly is invariably found in stud- 
ies employing frequent (QS-20 min) 
blood sampling (Barkan et al. 1989; 
Hartman et al. 1990; Roelfsema et al. 
1990). Whether these GH pulses repre- 
sent accelerated GHRH pulse frequency 
is still a matter of debate. The nocturnal 
augmentation of GH secretion is still 
present in patients with acromegaly, 
indicating persistent control of GH se- 
cretion by the CNS. Importantly, even 
after the GH-producing tumor is com- 
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Figure 3. Simplified scheme of neuroendocrine and intracellular events leading to so- 
matotroph proliferation and GH secretion. Upon binding of GHRH to its pituitary membrane 
receptor, the GHRH-receptor complex activates a G, protein by promoting replacement of GDP 
by GTP in the guanine nucleotide binding site of the a subunit (a,). The activated as then 
stimulates adenylate cyclase (AC), thus increasing production of CAMP. All effects of GHRH 
upon the somatotroph can be reproduced by CAMP (Billestrup et al. 1986). Somatostatin (SRIF) 
interferes with this process by activating the inhibitory G, protein that suppresses AC activity. 
An increased intracellular level of CAMP activates protein kinase A, which in turn 
phosphorylates the CAMP response element binding protein (CREB). Phosphorylated CREB 
binds to the promoter of the GHF-l-Pit-1 gene, thereby initiating its transcription. The 
resultant GHF-l-Pit-1 protein fulfills two functions: activation of GH gene transcription and 
induction of somatotroph proliferation (Castrillo et al. 1991). 
an apparently stable remission, GH pulse 
frequency remains abnormally rapid (Ho 
et al. 1991). These studies suggest that 
acromegaly may be a hypothalamic dis- 
ease caused by GHRH excess (presuma- 
bly, high frequency of GHRH pulses). 
GHRH-transgenic mice develop GH hy- 
persecretion, gigantism, and pituitary 
mammosomatotroph hyperplasia with 
subsequent adenoma formation (Asa et 
al. 1990). Interestingly, an identical mor- 
phologic picture was recently described 
in a child with acromegaly that was 
likely due to central GHRH excess (Zim- 
merman et al. 1991). 
On the other hand, absence of soma- 
totroph hyperplasia in the periadenoma- 
tous pituitary tissue and monoclonality 
of GH-producing tumors support the 
“pituitary” origin of acromegaly (Her- 
man et al. 1990). Although unquestiona- 
bly compelling, this evidence can hardly 
be regarded as final. Several models 
indicate that hormonal induction of pi- 
tuitary tumors may begin with hyperpla- 
sia that subsequently progresses into 
adenoma (Scheithauer et al. 1985). More- 
over, some pituitary tumors appear to be 
polyclonal (Schulte et al. 1991), and a 
transition from a polyclonal pattern to 
monoclonality has been demonstrated in 
other neoplasms (Woodruff et al. 1982). 
One can imagine, for example, that 
during the GHRH-induced process of 
somatotroph hyperplasia, elevated plasma 
IGF-I may cause physiologic involution 
of hyperplastic GH-producing cells, while 
one cell develops a resistance to the 
negative feedback of IGF-I and continues 
to proliferate, giving rise to a monoclo- 
nal adenoma. In support of this is the 
persistence of rapid GH pulsatility in 
acromegalic women with pregnancy- 
induced further elevation of IGF-I (Beck- 
ers et al. 1990) and the absence of 
acceleration of GH pulse frequency in 
acromegalics after fasting-induced fall 
in plasma IGF-I (Ho et al. 1990). 
Animals made transgenic for cholera 
toxin (Burton et al. 1991), thus having 
permanently activated adenylate cyclase 
(AC), develop pituitary hyperplasia and 
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gigantism. Other models of altered cAMP- 
dependent cascade, namely, insertion of 
a mutant CREB gene (Struthers et al. 
1991) or inhibition of GHF-l-Pit-1 syn- 
thesis (Castrillo et al. 199I), result in 
somatotroph hypoplasia and dwarfism. 
It is easy to imagine that different 
mutations may constitutively activate 
CREB or GHF-1, thereby producing so- 
matotroph hyperplasia and gigantism. 
Interestingly, in the GHRH-transgenic 
mice, no GHF-1 protein is detected 
within the hyperplastic pituitary soma- 
totrophs, while it is abundant in the 
areas of adenomatous transformation in 
the same pituitaries (Osamura et al. 
1992). Recently, two mutations in the a 
subunit of G, protein have been de- 
scribed in 40% of human somatotropi- 
nomas (Spada et al. 1990). These muta- 
tions lead to constitutive activation of 
AC, conceivably mimicking the effect of 
GHRH. The mutations have been pro- 
posed to be the mechanism of GHRH- 
independent formation of somatotropi- 
nomas. It is of interest, however, that the 
same mutations significantly increased 
mitogenic responsiveness of 3T3 cells to 
exogenous activation of AC (Zachary et 
al. 1990), bringing us back to the “two 
stage” hypothesis of pituitary oncogene- 
sis. Animals transgenic for an oncogene 
working outside of the “GHRH pathway” 
develop pituitary tumors incapable of 
secreting GH (Stefaneanu et al. 1992). 
In the majority of patients (>99%), 
acromegaly is due to a GH-producing 
pituitary tumor. Several histolic varie- 
ties of pituitary somatotropinomas have 
been described (Melmed 1990), and they 
may reflect different physiopathologic 
processes or different cellular precur- 
sors. Rarely, tumors may develop in the 
pharyngeal pituitary tissue (Warner et 
al. 1982). Since a pharyngeal pituitary 
remnant is present in everyone, the 
extreme rarity of tumor development in 
this structure is puzzling. Again, it is 
tempting to speculate that this is due to 
the absent hypothalamic input to the 
ectopic pituitary and that the primary 
cell mutation may not arise in the 
absence of hypothalamic stimulation or 
may by itself be insufficient to result in 
tumor formation. Interestingly, func- 
tional and morphologic survival of human 
somatotropinomas transplanted into nude 
mice is improved by GHRH administra- 
tion (Puchner et al. 1991). 
The ‘ectopic GHRH” syndrome is a 
rare but important form of acromegaly. 
Among some 30 patients described thus 
far (Sano et al. 1988), most had car- 
cinoid or islet-cell tumor as a source of 
ectopic GHRH. Usually, these patients 
have diffuse somatotroph hyperplasia as 
a manifestation of high circulating levels 
of GHRH (usually >l rig/ml), but occa- 
sionally a true pituitary adenoma may 
develop. In contrast, acromegaly due to a 
GHRH-producing hypothalamic or pitui- 
tary gangliocytoma is always associated 
with a true GH-secreting adenoma in- 
stead of hyperplasia (Asa et al. 1984). 
The reason for the morphologic differ- 
ence between the two forms of GHRH- 
induced disease is uncertain, but may be 
related to a difference in the duration of 
the disease process, since the “ectopic 
GHRH syndrome” may be diagnosed 
earlier, in the course of workup for 
metastatic carcinoid or islet-cell tumor. 
Indeed, as mentioned above, a transition 
from hyperplasia to adenoma has been 
demonstrated in GHRH-transgenic mice 
and in one patient with an apparently 
central source of GHRH hypersecretion. 
Recent description of GHRH mRNA in 
somatotropinomas, but not in other pi- 
tuitary tumors or in normal pituitary 
tissue, further blurs the distinction be- 
tween different types of acromegaly (Wa- 
kabayashi et al. 1992). 
In summary, the question of hypotha- 
lamic versus pituitary cause of 
acromegaly has not been resolved yet. 
The current in vivo studies are necessarily 
limited to an indirect assessment of 
GHRH secretion by measuring plasma 
GH profiles, whereas the in vitro investi- 
gations study the final morphologic prod- 
uct of the disease, that is, the tumor, and 
cannot draw any conclusions about the 
preexisting neurohormonal milieu to 
which this tissue had been exposed. The 
final answer is likely to come from in vivo 
studies in patients with acromegaly that 
will utilize recently developed methods: 
direct sampling of the pituitary portal 
blood (Paradisi et al. 1989) and the use of 
GHRH-receptor antagonists (Lumpkin et 
al. 1989) analogously to the use of G&U-I 
antagonist in patients with FSH-produc- 
ing tumors (Daneshdoost et al. 1990). 
Diagnosis 
Clinical presentation of a patient with 
acromegaly is usually straightforward 
and the clinical impression is easily 
confirmed by appropriate laboratory tests. 
Plasma GH is almost always elevated to 
>5 clg/L, but may fluctuate widely during 
the day. Traditionally, oral glucose load- 
ing has been used to substantiate the 
diagnosis, since plasma GH declines to 
c2 l&L in practically all normal sub- 
jects, but remains above this limit in all 
patients with acromegaly. Recent availa- 
bility of IGF-I assay further simplifies 
the diagnostic process. A single elevated 
IGF-I level in a patient with the appropri- 
ate clinical picture establishes the diag- 
nosis with 100% certainty. It is especially 
useful in rare patients whose plasma GH 
is only minimally elevated. One should 
be careful, however, in interpreting ele- 
vated IGF-I levels in pubertal children 
and in pregnant women, since IGF-I may 
be physiologically high in these circum- 
stances. In patients with acromegaly, 
plasma IGF-I levels increase almost line- 
arly following increase in mean plasma 
GH levels from normal up to -20 yg/L, 
and plateau thereafter (Barkan 1989). 
This explains the well-known fact that 
clinical severity of acromegaly does not 
correlate well with the magnitude of GH 
hypersecretion. Therapy should be aimed 
at lowering plasma GH to <2 pg/I_ to 
normalize IGF-I levels and provide mean- 
ingful clinical improvement. 
GH responses to a variety of provoca- 
tive stimuli are abnormal in patients 
with acromegaly. Of these, two carry 
clinical importance: a paradoxical fall to 
dopamine agonists is employed as a 
rationale for therapy (bromocriptine); 
and a paradoxical rise to TRH, seen in 
60%80% of patients, is helpful in detect- 
ing even minimally abnormal GH secre- 
tion after surgery. Unfortunately, the 
mechanism(s) of the GH rise to TRH in 
acromegaly is uncertain, and may relate 
either to the presence of the tumor or to 
GHRH excess. Recently, measurement 
of plasma GHRH has become available. 
Even though the diagnostic yield will be 
low, this assay should be performed in 
every newly diagnosed patient because it 
is the single best test to exclude the 
“ectopic GHRH syndrome.” GH responses 
to a variety of dynamic maneuvers (TRH, 
L-DOPA, glucose load, and GHRH) can- 
not differentiate between this condition 
and a simple pituitary tumor. The dis- 
tinction, however, is crucial because 
pituitary surgery in patients with ectopic 
GHRH secretion is of no value (any 
remnant of pituitary tissue will undergo 
additional hyperplasia and GH hyperse- 
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cretion will not abate), and unnecessary 
hypopituitarism is almost inevitable. Re- 
moval of the GHRH-producing tumor, 
on the other hand, is curative. 
Pituitary computed tomography or 
magnetic resonance imaging scan is 
necessary to delineate the size of the 
tumor and the degree of invasiveness. 
Most somatotropinomas are large by the 
time of diagnosis, measuring 2-3 cm in 
diameter and expanding into the cavern- 
ous sinuses, sphenoid sinus, or above the 
sella, abutting on the optic chiasm. In 
these patients, residual pituitary func- 
tion is frequently compromised. 
Therapy 
Surgery is the best treatment for almost 
all patients with newly diagnosed dis- 
ease. Only rarely would one prefer non- 
surgical treatment, that is, in an elderly 
patient with mild disease or in one 
whose general medical condition pre- 
cludes anesthesia. The operation should 
be carried out by an experienced pitui- 
tary neurosurgeon, because the first 
operation is often the last one, and 
repeat operation is rarely successful be- 
cause of distorted anatomy and intrasel- 
lar scarring. Most surgical series report 
an -75% cure rate in patients with 
enclosed microadenomas and a 20% 
30% cure rate in patients with large 
tumors (Ross and Wilson 1988). One 
should appreciate, however, that these 
data were generated from remarkably 
liberal criteria for cure, such as single 
GH <5 ug/L with or without glucose load. 
Most of these patients have persistently 
high plasma IGF-I, indicating active 
disease, and will require further therapy. 
Most often, radiation is administered in 
an attempt to destroy the residual pitui- 
tary tumor tissue. External pituitary 
radiation, proton beam, a particle, inter- 
stitial radiation, or stereotactic 6oCo beam 
(“y-knife”) (Thor-en et al. 1991) have been 
employed and none of these offers even 
marginal long-term advantage over the 
other. GH declines by -50% within the 
first 2 years after radiation, and by 
lo%-20% per year thereafter. Thus, the 
initial GH level is the crucial determi- 
nant of the final result, and patients with 
preradiation GH levels of >20 l.tg/L are 
unlikely to benefit from the procedure 
for at least S-10 years. Hypopituitarism 
develops in 50% of patients within 5 
years after radiation, but true normaliza- 
tion of the GH secretory rate is seen in 
~20%. Many endocrinologists are still 
reluctant to recommend radiation ther- 
apy for fear of side effects. However, 
modern techniques have practically elim- 
mated systemic side effects, and damage 
to distant brain structures is virtually 
never seen. The fear of decreased cogni- 
tive function appears to be unfounded 
because of the small radiation dose to 
cerebral hemispheres and the maturity 
of brain tissue in adult acromegalics. 
Furthermore, the balance between the 
minute theoretical possibility of brain 
dysfunction and the real dangers of 
persistent GH hypersecretion is clearly 
tilted toward the latter. Dopamine ag- 
onists, of which bromocriptine is the 
most popular, have beneficial effect in 
some patients. Unfortunately, even 
though they decrease plasma GH in half 
of the patients, only in 20%-25% of the 
cases does plasma GH decline to <5 l.tg/L, 
and plasma IGF-I becomes normal in no 
more than 10%15% of the patients 
(Barkan 1989). 
Somatostatin analogue SMS 201-995 
(Sandostatin or octreotide) represents 
the most powerful nonsurgical therapeu- 
tic modality (Barkan 1989). It is usually 
administered as 3-4 daily injections of 
SO-500 pg each or as a continuous 
subcutaneous infusion. The latter ap- 
pears to be more effective. Approxi- 
mately 90% of patients respond to this 
treatment and plasma GH and IGF-I can 
be normalized in 60%70% of cases. The 
acute side effects (abdominal cramps or 
diarrhea) are usually self-limited, but 
there is a high incidence of gallstone 
formation with long-term therapy. Nor- 
malization of GH secretion relieves 
arthropathy and cardiomyopathy of 
acromegaly. Interestingly, headaches dis- 
appear within minutes after the injec- 
tion, well before there is an effect on GH 
hypersecretion. Octreotide is the only 
effective therapy for a surgically incura- 
ble ectopic GHRH secretion by a car- 
cinoid tumor. 
Preoperative therapy with octreotide 
in patients with GH-producing mac- 
roadenomas appears to shrink and sof- 
ten the tumor in the majority of patients 
(Barkan et al. 1988). Preliminary data 
have suggested that this may result in a 
more favorable surgical outcome, and 
additional studies of this nature are 
needed. High doses of octreotide are 
probably necessary for this effect in 
patients with macroadenomas, because 
the morphologic effects of the drug are 
likely to parallel its ability to normalize 
GH hypersecretion. Pretreated tumors 
exhibit smaller cell size, perivascular 
fibrosis, and dense granularity. The drug 
is not tumoricidal, since cessation of 
therapy is followed by restoration of GH 
hypersecretion and by the reexpansion 
of the tumor. 
The year 1992 marks the 100th anni- 
versary of the first attempt to treat a 
patient with a GH-producing tumor 
(Caton and Paul 1893). This century 
brought remarkable advances in our 
ability to diagnose and to treat 
acromegaly, but crucial questions of the 
etiology and the physiologic and molecu- 
lar mechanisms involved remain unan- 
swered. Recent advances in molecular 
biology and development of novel physi- 
ologic paradigms will enable a better 
understanding of the physiopathology of 
this disease and more effective therapy. 
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